Khiron opens first Zerenia ™ clinic in Peru, prescribing medical cannabis products with high and low THC content to patients

0
147

Khiron founds a strategic partnership with the Lima-based Clinica Montesur. Zerenia’s first medical cannabis clinic

Tweet that

With over 30 years of experience in Peru, Clinica Montesur is dedicated to providing high quality care in 19 specialties including oncology, dermatology, ophthalmology and psychology. As part of the strategic partnership, Clinica Montesur will provide the clinic infrastructure, including the medical facility, clinic permits, systems and medical staff, among others. The partnership will leverage Khiron’s unique ZereniaTM medical cannabis model, including the company’s medical cannabis educational platform, real-world evidence and standard practices. Patients at the clinic can fill out high-THC and low-THC (CBD) medical cannabis prescriptions at ten Farmacia Universal SAC locations anywhere Limaas previously announced by the company.

About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis company with core businesses in Latin America and Europe. Leveraging wholly-owned medical health centers and proprietary telemedicine platforms, Khiron combines a patient-centered approach, physician education programs, scientific expertise, product innovation and agricultural infrastructure to drive prescribing and brand loyalty among patients worldwide. The company has a sales presence in Colombia, Peru, Germany and the UK and is able to sell in Mexico and Brazil in 2021. The company will be led by Co-Founder and Chief Executive Officer, Alvaro Torres placeholder image, along with an experienced and diverse leadership team and board of directors.

Visit Khiron online at investoren.khiron.ca and on Instagram @khironlife.

Warning notices

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron has no obligation to comment on any analysis, expectations, or statements by any third party regarding Khiron, its securities, or financial or operating results (if any). Although Khiron believes that the expectations reflected in the forward-looking statements in this press release are reasonable, such forward-looking statements are based on expectations, factors and assumptions about future events that could prove to be inaccurate and involve numerous risks and assumptions Subject to uncertainties some of which are beyond Khiron’s control, including the risk factors described in Khiron’s annual disclosure form available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly limited by this cautionary notice and is effective as of the date of this publication. Khiron disclaims any intention and assumes no obligation or responsibility except as required by law to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

similar links

https://khiron.ca/